生技藥品和生物相似藥市場規模、佔有率和成長分析：按產品類型、原料、治療應用、分銷管道和地區分類－2026-2033年產業預測

2024 年全球生技藥品和生物相似藥市場價值為 6,104.1 億美元，預計從 2025 年的 7,007.5 億美元成長到 2033 年的 2.11,397 兆美元，預測期（2026-2033 年）的複合年成長率為 14.8%。

全球生技藥品和生物相似藥市場涵蓋了多種源自活細胞的治療藥物，以及經監管部門批准後模仿現有生物製藥的產品，主要針對傳統小分子藥物療效不佳的慢性疾病的治療。市場成長的驅動力來自生物製藥獲批數量的增加以及對具成本效益替代方案的需求，例如主要單株抗體和生物相似藥的上市。監管協調和支付方需求的協同作用正在創造一個有利於生物相似藥推廣的環境，加快產品在各地區的上市速度。人工智慧透過標靶最佳化、縮短實驗週期和整合數據平台，提高了生物相似藥的研發效率，發揮變革性的作用。這項技術進步透過加快產品上市速度並滿足全球對生物製劑療法日益成長的需求，推動了整體市場的發展勢頭。

全球生技藥品和生物相似藥市場促進因素

全球生技藥品和生物相似藥市場正受到醫療服務提供者轉向使用具有標靶治療效果並能改善患者預後的生物製藥趨勢的顯著推動。隨著醫院和診所擴大將這些治療方法納入其治療方案，製藥公司被敦促專注於開發創新生物製藥及其生物相似藥，從而催生了蓬勃發展的新產品線。這種需求的激增促使製造商投入資源用於研發、法規遵循和生產技術改進，以滿足對先進治療方案日益成長的需求。此外，這種環境也促進了與契約製造的合作，從而加速了全球產品的供應。

全球生技藥品和生物相似藥市場的限制因素

全球生技藥品和生物相似藥市場面臨許多挑戰，主要源自生技藥品生產過程的極端複雜性。這些產品的生產需要先進的細胞培養技術、嚴格的純化過程以及專業的分析檢測。這種複雜性需要大量的資本投入和高技能的人員，從而導致更長的前置作業時間週期和更高的整體成本。這些壁壘阻礙了新進入者，並削弱了價格競爭力。因此，儘管市場需求不斷成長，企業往往不願擴大營運規模或推出創新產品，阻礙了市場擴張。此外，複雜的供應鏈也帶來了額外的風險；供應中斷會影響產品的供應以及對監管標準的合規性。

生技藥品和生物相似藥市場的全球趨勢

全球生技藥品和生物相似藥市場正經歷著向以患者為中心的重大轉變，這主要得益於人們對經濟實惠的治療方案的日益關注以及支付方激勵機制的獎勵。隨著生物相似藥的推廣管道被積極納入醫療保健系統的處方集，臨床醫生越來越傾向於選擇療效和安全性相當的生物相似藥。這有助於與尋求經濟有效的治療方案且不影響臨床療效的患者進行協作決策。為此，生產商正致力於加強患者支持項目、收集真實世界數據 (REW) 並提供透明的藥品標籤。這些努力正在加速市場滲透，生物相似藥的選擇正成為全球個人化治療策略不可或缺的一部分。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球生技藥品和生物相似藥市場規模：依產品類型分類

• 生物製劑
  • 原始單株抗體
  • 重組蛋白
  • 基因和細胞療法
• 生物相似藥
  • 單株抗體生物相似藥
  • 胰島素生物相似藥
  • 重組激素生物相似藥

全球生技藥品和生物相似藥市場規模：依原料分類

• 微生物細胞
  • 細菌細胞
  • 酵母菌細胞
• 哺乳動物細胞和動物細胞
• 植物細胞
• 其他來源

全球生技藥品和生物相似藥市場規模：依治療應用分類

• 腫瘤學
• 自體免疫疾病
• 糖尿病
• 血液疾病
• 心血管疾病
• 感染疾病
• 其他

全球生技藥品和生物相似藥市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 專科藥房
• 網路藥房

全球生技藥品和生物相似藥市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Amgen Inc.
• Sandoz International GmbH
• Pfizer Inc.
• Biogen Inc.
• F. Hoffmann-La Roche Ltd
• Samsung Bioepis Co. Ltd.
• Celltrion Inc.
• Viatris Inc.
• Eli Lilly and Company
• AbbVie Inc.
• Johnson & Johnson Services Inc.
• Merck & Co. Inc.
• Sanofi SA
• AstraZeneca plc
• Bristol Myers Squibb Company
• Teva Pharmaceutical Industries Ltd.
• Coherus BioSciences Inc.
• Organon & Co.
• Fresenius Kabi AG
• Biocon Biologics Limited

結論與建議

Global Biologics And Biosimilars Market size was valued at USD 610.41 Billion in 2024 and is poised to grow from USD 700.75 Billion in 2025 to USD 2113.97 Billion by 2033, growing at a CAGR of 14.8% during the forecast period (2026-2033).

The global biologics and biosimilars market encompasses a range of therapeutics derived from living cells and products that imitate established biologics after regulatory approval, primarily addressing chronic conditions where traditional small-molecule drugs may not suffice. Market growth is fueled by the rise in biologic approvals and the demand for cost-effective alternatives, exemplified by the launch of key monoclonal antibodies and biosimilars. The synergy between regulatory harmonization and payer demands fosters an environment conducive to biosimilar adoption, facilitating quicker product launches across regions. AI plays a transformative role by enhancing biosimilar development efficiency through optimized target selection, reduced experimental cycles, and integrated data platforms. This technological advancement supports faster market entry and meets the expanding global demand for biologic therapies, bolstering overall market momentum.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biologics And Biosimilars market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biologics And Biosimilars Market Segments Analysis

Global biologics and biosimilars market is segmented by product type, source, therapeutic application, distribution channel and region. Based on product type, the market is segmented into Biologics and Biosimilars. Based on source, the market is segmented into Microbial Cells, Mammalian and Animal Cells, Plant Cells and Other Sources. Based on therapeutic application, the market is segmented into Oncology, Autoimmune Diseases, Diabetes, Hematological Disorders, Cardiovascular Disorders, Infectious Diseases and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Biologics And Biosimilars Market

The Global Biologics and Biosimilars market is being significantly driven by the transition among healthcare providers towards biologic therapies, which deliver targeted therapeutic benefits and enhance patient outcomes. As hospitals and clinics increasingly incorporate these therapies into their treatment protocols, pharmaceutical companies are motivated to focus on the development of innovative biologics and their biosimilars, leading to a vibrant pipeline of new products. This surge in interest results in manufacturers dedicating resources to research, regulatory compliance, and manufacturing advancements, all aimed at satisfying the rising demand for sophisticated therapeutic solutions. Additionally, this environment fosters partnerships with contract manufacturers, thereby expediting global product availability.

Restraints in the Global Biologics And Biosimilars Market

The Global Biologics and Biosimilars market faces significant challenges due to the intricate nature of biologic and biosimilar production, which requires advanced cell culture techniques, rigorous purification processes, and specialized analytical testing. These complexities necessitate considerable capital investment and highly skilled personnel, resulting in extended lead times and increased overall costs. Such barriers deter new entrants and compromise price competitiveness. As a result, companies may be reluctant to scale operations or introduce innovative products, hindering market expansion despite growing demand. Additionally, the complicated supply chain introduces further risks, as disruptions can impact product availability and adherence to regulatory standards.

Market Trends of the Global Biologics And Biosimilars Market

The Global Biologics and Biosimilars market is experiencing a significant shift toward patient-centric adoption, driven by a growing awareness of treatment affordability and enhanced payer incentives. Clinicians are increasingly prioritizing biosimilars that offer comparable efficacy and safety, as healthcare systems actively integrate biosimilar pathways into formularies. This fosters shared decision-making with patients, who are seeking cost-effective treatment options without compromising clinical outcomes. In response, manufacturers are enhancing patient support programs, generating real-world evidence, and providing transparent labeling. These initiatives are facilitating faster market penetration and establishing biosimilar choice as an integral part of personalized therapy strategies on a global scale.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Biologics and Biosimilars Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Biologics
  • Innovator Monoclonal Antibodies
  • Recombinant Proteins
  • Gene and Cell Therapies
• Biosimilars
  • Monoclonal Antibody Biosimilars
  • Insulin Biosimilars
  • Recombinant Hormone Biosimilars

Global Biologics and Biosimilars Market Size by Source & CAGR (2026-2033)

• Market Overview
• Microbial Cells
  • Bacterial Cells
  • Yeast Cells
• Mammalian and Animal Cells
• Plant Cells
• Other Sources

Global Biologics and Biosimilars Market Size by Therapeutic Application & CAGR (2026-2033)

• Market Overview
• Oncology
• Autoimmune Diseases
• Diabetes
• Hematological Disorders
• Cardiovascular Disorders
• Infectious Diseases
• Others

Global Biologics and Biosimilars Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• Online Pharmacies

Global Biologics and Biosimilars Market Size & CAGR (2026-2033)

• North America (Product Type, Source, Therapeutic Application, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Source, Therapeutic Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Source, Therapeutic Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Source, Therapeutic Application, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Source, Therapeutic Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus BioSciences Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organon & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Biologics Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations